Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tumor testing cost-effective for triage to germline testing in HGSOC patients

Publish date:: March 17, 2019

Key clinical point: Tumor testing for triage of HGSOC patient to confirmatory genetic testing may be cost-effective.

Major finding: Tumor testing yields an incremental cost-effectiveness ratio (ICER) of $127,000 per year of life gained.

Study details: A cost-efficacy analysis.

Disclosures: Dr. Kwon has received research funding from AstraZeneca.

Citation:

Kwon J et al. SGO 2019: Abstract 5.

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,